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Abstract
Background: There has been insufficient examination of the factors affecting long-term survival of more than
5 years in patients with leukemia that is not in remission at transplantation.
Method: We retrospectively analyzed leukemia not in remission at allogeneic hematopoietic cell transplantation
(allo-HCT) performed at our institution between January 1999 and July 2009. Forty-two patients with a median
age of 39 years received intensified conditioning (n = 9), standard (n = 12) or reduced-intensity conditioning
(n = 21) for allo-HCT. Fourteen patients received individual chemotherapy for cytoreduction during the three
weeks prior to reduced-intensity conditioning. Diagnoses comprised acute leukemia (n = 29), chronic myeloid
leukemia-accelerated phase (n = 2), myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) (n = 10) and
plasma cell leukemia (n = 1). In those with acute leukemia, cytogenetic abnormalities were intermediate (44%)
or poor (56%). The median number of blast cells in bone marrow (BM) was 26.0% (range; 0.2-100) before the
start of chemotherapy for allo-HCT. Six patients had leukemic involvement of the central nervous system. Stem
cell sources were related BM (7%), related peripheral blood (31%), unrelated BM (48%) and unrelated cord blood
(CB) (14%).
Results: Engraftment was achieved in 33 (79%) of 42 patients. Median time to engraftment was 17 days (range:
9-32). At five years, the cumulative probabilities of acute graft-versus-host disease (GVHD) and chronic GVHD
were 63% and 37%, respectively. With a median follow-up of 85 months for surviving patients, the five-year
Kaplan-Meier estimates of leukemia-free survival rate and overall survival (OS) were 17% and 19%, respectively.
At five years, the cumulative probability of non-relapse mortality was 38%. In the univariable analyses of the
influence of pre-transplant variables on OS, poor-risk cytogenetics, number of BM blasts (>26%), MDS overt AML
and CB as stem cell source were significantly associated with worse prognosis (p = .03, p = .01, p = .02 and
p < .001, respectively). In addition, based on a landmark analysis at 6 months post-transplant, the five-year
Kaplan-Meier estimates of OS in patients with and without prior history of chronic GVHD were 64% and 17%
(p = .022), respectively.
Conclusion: Graft-versus-leukemia effects possibly mediated by chronic GVHD may have played a crucial role in
long-term survival in, or cure of active leukemia.
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Patients with primary refractory or refractory relapsed
acute leukemia have an extremely poor prognosis. It has
been generally recognized that few cases with primary
refractory or refractory relapsed acute leukemia can be
cured using conventional chemotherapy alone [1]. While
allogeneic hematopoietic cell transplantation (allo-HCT)
has the potential to cure even active leukemia, it has not
been determined what subgroup can receive a long-term
benefit from it.
Several retrospective studies have reported the prog-
nostic factors for allo-HCT in patients not in remission
at allo-HCT including untreated first relapse cases [2-8].
However, the factors contributing to long-term survival
have not been established because the follow-up periods
of these studies were not long enough at less than five
years. Importantly, it can be assumed that patients who
survive for more than five years without leukemia
relapse are most likely cured. Only one large-scale retro-
spective study has examined long-term outcomes for
more than five years following allo-HCT in adult
patients with acute leukemia not in remission [9]. This
study showed that several pre-transplant variables
including complete remission duration, type of donor,
disease burden, performance status, age and cytogenetics
affected survival. However, whether post-transplant vari-
ables such as acute or chronic graft-versus-host disease
(GVHD) influenced the post-HCT prognosis was not
assessed. To our knowledge, no studies have investigated
pre- and/or post-transplant factors which are associated
with long-term survival exclusively in adult patients
with active leukemia at allo-HCT. Therefore, we com-
prehensively evaluated the pre- and post-transplant fac-
tors which contribute to long-term survival of more
than five years in patients with leukemia not in remis-
sion at allo-HCT.
Patients and methods
Between January 1999 and July 2009, 42 consecutive
patients (24 males and 18 females) with leukemia not in
remission, aged 15 to 67 years (median age: 39 years),
underwent allo-HCT at our institution. Patients with de
novo acute myeloid leukemia (AML; n = 17), acute lym-
phoblastic leukemia (ALL; n = 12), chronic myeloid leu-
kemia in accelerated phase (CML-AP; n = 2),
myelodysplastic syndrome (MDS) overt AML (n = 10)
and plasma cell leukemia (n = 1) were included. High-
risk AML was defined according to the Eastern Coop-
erative Oncology Group/Southwest Oncology Group
classification as having poor-risk cytogenetics (5/del[5q],
7/del[7q], inv[3q], abn11q, 20q or 21q, del[9q], t[6;9], t
[9;22], abn17p, and complex karyotype defined as three
or more abnormalities) [10]. High-risk ALL was defined
as having poor-risk cytogenetics with either t(4:11), t
( 9 ; 2 2 ) ,t ( 8 ; 1 4 ) ,h y p o d i p l o idy or near triploidy, or more
than five cytogenetic abnormalities [11]. Of study sub-
jects with acute leukemia, cytogenetic abnormalities
were intermediate (n = 17, 44%) or poor (n = 22, 56%).
Seven patients were primary refractory to induction che-
motherapy. The other patients relapsed after conven-
tional chemotherapy (n = 23) or the first or the second
HCT (n = 9). The median number of blast cells in bone
marrow (BM) was 26.0% (range; 0.2-100) before the
start of chemotherapy for allo-HCT. Six patients had
leukemic involvement of the central nervous system
(CNS). Stem cell sources were related BM (n = 3, 7%),
related peripheral blood (PB) (n = 13, 31%), unrelated
BM (n = 20, 48%) and unrelated cord blood (CB) (n =
6, 14%). Standard serologic typing was used for human
leukocyte antigen (HLA) -A, B and DRB1. Thirty-one
pairs were matched for HLA-A, B and DRB1 antigens.
Three patients were mismatched for one HLA antigen
( t w oa tH L A - A ,o n ea tH L A - B ) ,a n ds e v e nw e r em i s -
matched for two (two at HLA-A and B, five (all CB) at
HLA-B and DRB1). The remaining one patient was mis-
matched for all three antigens (haploidentical). We clas-
sified conditioning regimens into four categories.
Standard conditioning (n = 12) comprised a busulfan-
based or total body irradiation (TBI)-based (12Gy) regi-
men. Busulfan was given as a total of 16 mg/kg orally or
equivalent dose, 12.8 mg/kg intravenously (i.v.). Intensi-
fied conditioning (n = 9) consisted of additional cytore-
ductive chemotherapy in the three weeks before
conditioning, followed by standard conditioning. Of the
21 patients receiving standard or intensified condition-
ing, 13 patients received the TBI-based regimen.
Reduced-intensity conditioning (n = 21) comprised a
fludarabine-based (n = 20) and cladribine-based regimen
(n = 1). Fludarabine was given as 25-35 mg/m
2 i.v. on
five or six consecutive days. Of the 21 patients receiving
reduced-intensity conditioning, 14 patients received
cytoreductive chemotherapy in the three weeks before
conditioning. Prophylaxis for acute GVHD was a calci-
neurin inhibitor alone (n = 5), calcineurin inhibitor plus
short-term methotrexate (n = 32), calcineurin inhibitor
plus mycophenolate mofetil (n = 2), or none (n = 3).
The calcineurin inhibitor included cyclosporine adminis-
tered to 33 patients and tacrolimus to six patients.
End points
The absence of post-transplant remission in some
patients biased the calculation of relapse rate, nonre-
lapse mortality (NRM) and leukemia-free survival
(LFS). Therefore, we set five-year overall survival (OS)
as the primary end point. OS was defined as time from
the date of last transplantation to the date of death or
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of last transplantation to the date of disease relapse,
death during remission or last follow-up. NRM was
defined as a death not related to disease. Neutrophil
recovery was defined as an absolute neutrophil count
of at least 500 cells/mm
3 for three consecutive time
points. Platelet recovery was defined as a count of at
least 20 000 platelets/mm
3 without transfusion sup-
port. Acute GVHD (aGVHD) was defined in accor-
dance with standard criteria [12]. Chronic GVHD
(cGVHD) was evaluated in patients surviving for more
than 100 days after allo-HCT and was classified into
limited or extensive type [13].
Statistical analysis
If the disease for which the patient underwent trans-
plantation was present at the time of death or found at
autopsy, we defined disease relapse/progression as the
primary cause of death. Unadjusted survival probabilities
were estimated using the Kaplan and Meier method and
compared using the log-rank tests. Cumulative incidence
curves were used in a competing-risks model to calcu-
late the probability of aGVHD, cGVHD and NRM [14].
For neutrophil and platelet recovery, death before neu-
trophil or platelet recovery was the competing event; for
GVHD, death without GVHD and relapse were the
competing events; and, for NRM, relapse was the com-
peting event. In order to examine the impact of cGVHD
on survival, we performed a landmark analysis, which
divided patients according to their prior history of
cGVHD at 6 months post-transplant [15]. We excluded
from landmark analysis patients who died or relapsed
less than 6 months after transplant, and did not use the
information on whether or not patients developed
cGVHD 6 months after transplant. Multivariable analy-
sis of prognostic factors for the primary outcome could
not be conducted due to lack of statistical power.
Instead, we performed a landmark analysis, which
divided patients according to the significant pre-trans-
plant factors and their prior history of cGVHD at 6
months post-transplant. All P values were 2-tailed and
considered statistically significant if the values were less
than 0.05. All statistical analyses were performed using
the PASW Statistics17.0 (SPSS Inc, Chicago, IL, USA)
and the statistical software environment R, version 2.9.1.
Results
The baseline characteristics of the patients are shown in
Table 1.
Engraftment
Neutrophil engraftment was achieved in 33 (79%) of 42
patients. The median time to neutrophil engraftment was
17 days (range, 9-32). In a total of four of 27 evaluable
patients, a platelet count > 20 000/μl was not achieved.
In the patients that achieved platelet counts of ≥ 20 000/
μl, the median time to platelet engraftment was 33 days
(range, 13-99). The cumulative probabilities of neutrophil
and platelet engraftment were 79% and 55%, respectively.
GVHD
Twenty-four of 42 patients developed aGVHD (eight
grade I, nine grade II, five grade III, two grade IV).
Twelve of 24 evaluable patients developed cGVHD (one
Table 1 Baseline characteristics of study participants
Variable n (%) Median
(Range)
Male sex 24 (57.1)
Diagnosis
de novo AML 17 (40.5)
ALL 12 (28.6)
CML-AP 2 (4.8)
MDS overt AML 10 (23.8)
PCL 1 (2.4)
Cytogenetics
Intermediate 17
Poor 22
ECOG PS
0 2 (4.8)
1 25 (59.5)
2 7 (16.7)
3 8 (19.0)
Status at allo-HCT
Primary refractory/Refractory
relapse/Untreated MDS overt AML
7/32/3
No. chemo regimens prior allo-HCT 6 (0-18)
Time from diagnosis to allo-HCT (days) 319 (23-3738)
Marrow blasts at allo-HCT 26.0 (0.2-100)
Conditioning regimen
Intensified 9 (21.4)
Standard 12 (28.6)
Reduced-intensity 7 (16.7)
Reduced-intensity + cytoreductive
chemotherapy
14 (33.3)
GVHD prophylaxis
None 3 (7.1)
Calcineurin inhibitor alone 5 (11.9)
Calcineurin inhibitor + sMTX 32 (76.2)
Calcineurin inhibitor + MMF 2 (4.8)
Donor (HLA-A, B and DRB1 antigens)
Matched related PB/BM 10/2
Mismatched related PB/BM 3/1
Matched unrelated BM 19
Mismatched unrelated BM 1
Umbilical cord blood 6
allo-HCT: allogeneic hematopoietic cell transplantation; HLA: human leukocyte
antigen; sMTX: short-term methotrexate; MMF: mycophenolate motefil; BM:
bone marrow; PB: peripheral blood.
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probabilities of aGVHD and cGVHD were 63% and
37%, respectively.
NRM
A total of eight patients were alive at the time of this
analysis, seven in complete remission (CR). The most
common cause of death was disease relapse/progression.
Causes of death were disease relapse/progression (n =
2 7 ) ,G V H D( n=2 ) ,s i n u s o i d a lo b s t r u c t i o ns y n d r o m e
(SOS) (n = 3), Epstein-Barr virus associated post-trans-
plant lymphoproliferative disorder (n = 1), and adeno-
virus infection (n = 1). Of six patients with CNS lesion,
five died of disease relapse/progression (n = 3), GVHD
( n=1 )a n dS O S( n=1 ) ,a n do n ew a sa l i v ea tl a s tf o l -
low-up although another HCT was planned due to BM
relapse post-transplant. At five years, the cumulative
probability of NRM was 38%. Nine patients died before
day 30, and 18 patients died within the first 100 days
post-HCT.
LFS and OS
A total of 22 of 33 evaluable patients attained a CR after
the allo-HCT. The median follow-up of survivors was 85
months (range, 24-126 months). The five-year Kaplan-
Meier estimates of LFS and OS were 17% and 19%,
respectively.
Univariable analysis
We analyzed the impact of pre- and post-transplant
characteristics on OS after allo-HCT. The factors
included age at transplant, sex, primary vs. secondary
leukemia, cytogenetics at diagnosis, number of BM
blasts, donor type, myeloablative vs. reduced-intensity
conditioning, and presence or absence of acute and
chronic GVHD. Results of univariable analysis for OS
are summarized in Table 2. In the univariable analyses
of the impact of pre-transplant variables on OS, poor-
risk cytogenetics, number of BM blasts (>26%), MDS
overt AML and CB as stem cell source were significantly
associated with worse prognosis (p = .03, p = .01, p =
.02 and p < .001, respectively). In addition, based on a
landmark analysis at 6 months post-transplant, the five-
year Kaplan-Meier estimates of OS in patients with and
without prior history of cGVHD were 64% and 17% (p
= .022) respectively (Figure 1).
Bivariable analysis
We performed the landmark analyses at 6 months post-
transplant, which classified patients according to signifi-
cant pre-transplant factors including poor-risk cytoge-
netics, number of BM blasts, or secondary leukemia and
their prior history of cGVHD at 6 months post-trans-
plant. Results of bivariable analysis for OS are shown in
Figure 2, Figure 3 and Figure 4. The groups of patients
with intermediate cytogenetics, marrow blast ≤ 26% or
primary leukemia, who developed cGVHD less than 6
months after transplant, showed significantly or border-
line significantly higher survival rates than those in the
other groups (p = .039, p = .147, and p = .060, respec-
tively). The five-year Kaplan-Meier estimates of OS in
the patients with intermediate cytogenetics, marrow
blast ≤ 26% or primary leukemia in addition to prior
history of cGVHD were 75%, 83%, and 64%, respectively.
Discussion
Our data showed that allo-HCT resulted in long-term
disease remission and an eventual cure of active leuke-
mia in a subset of de novo AML or ALL patients with
marrow blast ≤ 26% and without poor-risk cytogenetics,
possibly by graft-versus-leukemia (GVL) effects
mediated through cGVHD.
A retrospective study with a large cohort using data
reported to the Center for International Blood and Mar-
row Transplant Research demonstrated that pre-trans-
plant variables delineated subgroups with different long-
Table 2 Univariable analysis of impact of pre-transplant
variables on overall survival
Variable Survival
(% at 5 y)
Log rank
P value
Age at allo-HCT
< 40 28 0.055
≥ 40 6
Diagnosis
MDS overt AML 0 0.015
Others 25
Cytogenetics
intermediate 35 0.013
poor 5
Marrow blasts at allo-HCT
≤ 26 33 0.013
>2 6 5
Donor source
Umbilical cord blood 0 <0.001
Others 22
Conditioning
Intensified 22 0.087
Standard 42
Reduced-intensity 0
Reduced-intensity + cytoreductive
chemotherapy
7
allo-HCT: allogeneic hematopoietic cell transplantation.
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leukemia not in remission [9]. However, they did not
address the effect of cGVHD on survival. Baron et al.
have reported that extensive cGVHD was associated
with decreased risk of progression or relapse in patients
with AML or MDS in complete remission at the time of
nonmyeloablative HCT [16]. However, it remains
unclear whether cGVHD is associated with long-term
disease control in patients who have active leukemia at
transplant. The results of the current study showed that
GVL effects mediated by cGVHD may play a crucial
role in long-term survival in or a cure of active leuke-
mia, especially in patients without poor-risk cytoge-
netics. Further study on the possible relationship
between cGVHD and GVL effects would be very helpful
in the management of immunosuppressive treatment.
For patients who were ineligible for myeloablative
conditioning due to comorbidities coupled with rapidly
progressive leukemia, we administered sequential cytore-
ductive chemotherapy, followed by reduced-intensity
conditioning for allo-HCT in order to reduce toxicity
and obtain sufficient anti-leukemic efficacy. The utility
of the combination of sequential cytoreductive che-
motherapy and reduced-intensity conditioning for allo-
HCT was previously reported [17]. Our results did not
Figure 1 Kaplan-Meier estimates of overall survival based on a
landmark analysis at 6 months post-transplant, grouping
patients according to prior history of cGVHD (p = .022). The 5-
year survival rates of patients with and without prior history of
cGVHD were 64% and 17%, respectively.
Figure 2 Kaplan-Meier estimates of overall survival based on a
landmark analysis at 6 months post-transplant, grouping
patients according to cytogenetics and prior history of cGVHD
(p = .039). The 5-year survival rates of patients with intermediate &
prior history of cGVHD +, poor & prior history of cGVHD +, and poor
& prior history of cGVHD - were 75%, 33%, and 20%, respectively.
Figure 3 Kaplan-Meier estimates of overall survival based on a
landmark analysis at 6 months post-transplant, grouping
patients according to percent marrow blast (≤ or > 26%) at
baseline and prior history of cGVHD (p = .147). Patients with
CNS lesion were not included in this analysis. The 5-year survival
rates of patients with fewer blast & prior history of cGVHD +, higher
blast & prior history of cGVHD +, and fewer blast & prior history of
cGVHD - were 83%, 33%, and 25%, respectively.
Koh et al. Journal of Experimental & Clinical Cancer Research 2011, 30:36
http://www.jeccr.com/content/30/1/36
Page 5 of 7show that this sequential regimen had an advantage in
controlling active leukemia. However, we speculated
that effective tumor reduction by individual chemother-
apy and/or conditioning for allo-HCT to control disease
until cGVHD subsequently occurred might also be
important, particularly in rapidly proliferating leukemia.
In contrast, intensive conditioning did not appear to be
essential in relatively indolent leukemia, even with non-
remission.
Based on our results, CB might be unsuitable as a
source of stem cells for treatment of active leukemia at
the time of allo-HCT. However, most patients receiving
CBT could not wait for an unrelated donor search
because their disease tended to be aggressive compared
with those in the unrelated BM group. Thus, it is diffi-
cult to arrive at any conclusions about the best stem
cell source for allo-HCT in patients in non-remission
status based solely on our results.
Our study has several limitations. The results might be
affected by an underlying selection bias due to the nat-
ure of retrospective data. Also, our study was limited by
the small number of patients, the heterogeneity of the
disease, the transplant procedure and the stem cell
source. However, the major strengths of our study were
that the follow-up period was sufficient with more
than 5 years and the impact of cGVHD as well as
pre-transplant factors on long-term survival were ana-
lyzed exclusively for subjects with active leukemia.
Conclusion
These data show that allo-HCT has the potential to cure
active leukemia possibly via cGVHD, particularly in
patients with favorable factors even when in non-remis-
sion. Further research is warranted to explore the essen-
tial factors contributing to the success of allo-HCT such
as intensity of conditioning, and GVL effects mediated
through cGVHD.
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